AgomAb Therapeutics (NASDAQ:AGMB) Research Coverage Started at B. Riley Financial

B. Riley Financial assumed coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research note released on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $34.00 price objective on the stock.

Separately, HC Wainwright began coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ:AGMB opened at $12.51 on Thursday. AgomAb Therapeutics has a 1-year low of $8.75 and a 1-year high of $17.82. The business’s fifty day simple moving average is $11.79.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.